First-line chemotherapy in very elderly patients with metastatic pancreatic cancer:Gemcitabine monotherapy vs combination chemotherapy
作者机构：Department of Internal Medicine and Biomedical Research InstituteDivision of GastroenterologyPusan National University HospitalBusan 49241South Korea Department of Internal Medicine and Biomedical Research InstituteDivision of Hematology-OncologyPusan National University HospitalBusan 49241South Korea Department of RadiologyBiomedical Research InstitutePusan National University HospitalBusan 49241South Korea Department of SurgeryBiomedical Research InstitutePusan National University HospitalBusan 49241South Korea
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2020年第8卷第18期
页 面：4022-4033页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by The National Research Foundation of Korea(NRF)grant funded by the Korea government(MSIT) No.2018R1C1B5086234
主 题：Combination chemotherapy Gemcitabine Pancreatic cancer Elderly Ductal carcinoma Adverse drug event
摘 要：BACKGROUND Combination chemotherapy(gemcitabine plus nab-paclitaxel and FOLFIRINOX)is widely used as the standard first-line treatment for pancreatic *** the severe toxicities of combination chemotherapy,gemcitabine monotherapy(G mono)could be used as a first-line treatment in very elderly patients or those with a low Eastern Cooperative Oncology Group ***,reports on the efficacy of G mono in patients older than 75 years are *** To evaluate the efficacy of G mono and combination chemotherapy by comparing their clinical outcomes in very elderly patients with pancreatic *** We retrospectively analyzed 104 older patients with pancreatic cancer who underwent chemotherapy with G mono(n=45)or combination therapy(n=59)as a first-line treatment between 2011 and *** patients were histologically diagnosed with ductal *** outcomes were progression-free survival and overall *** also analyzed subgroups according to age[65-74 years(elderly)and≥75 years(very elderly)].Propensity score matching was performed to compare the outcomes between the two chemotherapy *** The baseline characteristics were significantly different between the two chemotherapy groups,especially regarding age,ratio of multiple metastases,tumor burden,and Eastern Cooperative Oncology Group performance *** propensity score matching,the baseline characteristics were not significantly different between the chemotherapy groups in elderly and very elderly *** the elderly patients,the median progression-free survival(62 d vs 206 d,P=0.000)and overall survival(102 d vs 302 d,P=0.000)were longer in the combination chemotherapy ***,in the very elderly patients,the median progression-free survival(147 d and 174 d,respectively,P=0.796)and overall survival(227 d and 211 d,respectively,P=0.739)were comparable between the G mono and combination chemotherapy *** events occurred more frequently in the c
维普期刊数据库